Table 3.
Ongoing (not yet recruiting; recruiting; enrolling by invitation; active, not recruiting) clinical trials with monoclonal antibodies other than rituximab in combination with vincristine on patients suffering from various types of cancer (May 2021).
| Monoclonal Antibody | Trade Name | Manufacturer | Molecular Target | Condition | Trial Identifier | Ref. |
|---|---|---|---|---|---|---|
| Tafasitamab | Monjuvi® | MorphoSys, Planegg, Germany | CD19 1 | Diffuse large B-cell lymphoma | NCT04824092 | [125] |
| NCT04661007 | [126] | |||||
| NCT04134936 | [127] | |||||
| Atezolizumab | Tecentriq® | Roche, Basel, Switzerland | Programmed cell death-ligand 1 | Solid tumors | NCT04796012 | [148] |
| Nivolumab | Opdiva® | Bristol-Myers Squibb, New York, NY, USA | Primary mediastinal (thymic) large B-cell lymphoma | NCT04759586 | [149] | |
| Peripheral T-cell lymphoma | NCT03586999 | [150] | ||||
| Various lymphoma types | NCT03749018 | [151] | ||||
| NCT03704714 | [152] | |||||
| Toripalimab | Tuoyi® | Junshi Biosciences, Shanghai, China | NCT04058470 | [153] | ||
| Pembrolizumab | Keytruda® | Merck & Co., Kenilworth, IL, USA | NCT04058470 | [153] | ||
| Classical Hodgkin lymphoma | NCT03407144 | [154] | ||||
| Camrelizumab | AiRuiKa® | Jiangsu Hengrui Medicine, Lianyungang, China | NCT04113226 | [155] | ||
| Durvalumab | Imfinzi® | MedImmune, Gaithersburg, MD, USA | Large B-cell lymphoma | NCT03003520 | [156] | |
| Sintilimab | Tyvyt® | Eli Lilly and Company, Indianapolis, IN, USA | Epstein-Barr virus-positive diffuse large B-cell lymphoma | NCT04181489 | [157] | |
| Diffuse large B-cell lymphoma | NCT04023916 | [158] | ||||
| Avelumab | Bavencio® | EMD Serono, Rockland, USA; Pfizer, New York, NY, USA | Non-Hodgkin B-cell lymphoma | NCT03244176 | [159] | |
| Ublituximab | n.a. 2 | LFB Group, Alès, France | CD20 | Mantle cell lymphoma | NCT04692155 | [116] |
| Blinatumomab | Blincyto® | Amgen, Thousand Oaks, CA, USA | CD19, CD3 | B-cell acute lymphoblastic leukemia | NCT03518112 | [128] |
| NCT04448834 | [129] | |||||
| NCT03914625 | [130] | |||||
| Various leukemia types | NCT03147612 | [131] | ||||
| B-cell acute lymphoblastic leukemia and lymphoma | NCT02877303 | [132] | ||||
| Acute lymphoblastic leukemia | NCT03643276 | [133] | ||||
| NCT02003222 | [134] | |||||
| Daratumumab | Darzalex® | Janssen Biotech, Horsham, PA, USA | CD38 | Various types of lymphoma | NCT04139304 | [139] |
| Precursor cell lymphoblastic leukemia and lymphoma | NCT03384654 | [140] | ||||
| Isatuximab | Sarclisa® | Sanofi, Paris, France | Acute lymphoblastic leukemia, acute myeloid leukemia | NCT03860844 | [141] | |
| Inotuzumab | Besponza® | Pfizer, New York, NY, USA | CD22 | Recurrent and refractory B-cell lymphoma and leukemia | NCT03991884 | [162] |
| NCT03851081 | [163] | |||||
| NCT02981628 | [164] | |||||
| Acute lymphoblastic leukemia | NCT03249870 | [165] | ||||
| B-cell acute lymphoblastic leukemia and lymphoma | NCT02877303 | [132] | ||||
| Various leukemia types | NCT01925131 | [166] | ||||
| Lymphoblastic leukemia | NCT04747912 | [167] | ||||
| NCT04307576 | [168] | |||||
| B-acute lymphoblastic leukemia | NCT03150693 | [169] | ||||
| NCT01371630 | [170] | |||||
| Obinutuzumab | Gazyva® | Genentech, South San Francisco, CA, USA | CD20 | Advanced follicular lymphoma | NCT03817853 | [171] |
| B-cell lymphoma, non-Hodgkin lymphoma | NCT03467373 | [118] | ||||
| Follicular lymphoma | NCT03269669 | [172] | ||||
| Lymphoma | NCT02529852 | [173] | ||||
| Non-Hodgkin lymphoma | NCT01332968 | [174] | ||||
| Dinutuximab | Unituxin® | United Therapeutics, Silver Spring, MD, USA | Ganglioside G2 | Ganglioneuroblastoma, high risk neuroblastoma | NCT03786783 | [160] |
| Mosunetuzumab | - | Genentech, South San Francisco, CA, USA | CD20, CD3 | B-cell non-Hodgkin lymphoma | NCT03677141 | [117] |
| Polatuzumab | Polivy® | CD79B | Various lymphoma types | NCT04231877 | [145] | |
| Diffuse large B-cell lymphoma | NCT03274492 | [146] | ||||
| Brentuximab | Adcetris® | Takeda Oncology, Cambridge, CA, USA | CD30 | NCT02734771 | [135] | |
| Hodgkin lymphoma | NCT02398240 | [136] | ||||
| NCT02166463 | [137] | |||||
| NCT01920932 | [138] | |||||
| Ganitumab | - | Amgen, Thousand Oaks, CA, USA | Type 1 insulin-like growth factor receptor | Solid tumors | NCT02306161 | [161] |
| Ofatumumab | Arzerra® | Novartis, Basel, Switzerland | CD20 | Mantle cell lymphoma | NCT01527149 | [119] |
| Glofitamab | - | Genentech, South San Francisco, CA, USA | Diffuse large B-cell lymphoma | NCT03467373 | [118] | |
| Siplizumab | - | BioInvent, Lund, Sweden | CD2 | T-cell lymphoma | NCT01445535 | [121] |
| Alemtuzumab | Campath® | Sanofi, Paris, France | CD52 | Hodgkin lymphoma, diffuse large B-cell lymphoma | NCT01030900 | [142] |
| T-cell lymphoma | NCT00069238 | [143] | ||||
| Acute lymphoblastic leukemia | NCT01256398 | [144] |
1 cluster of differentiation; 2 a trading name not available.